12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine

Lancet Infect Dis. 2024 Dec;24(12):e729-e731. doi: 10.1016/S1473-3099(24)00615-7. Epub 2024 Oct 7.

Authors

Affiliations

¹ Meiji Seika Pharma, Chuo-ku, Tokyo, Japan.
² Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo, Japan.
³ Arcturus Therapeutics, San Diego, CA, USA.
⁴ Walson Consulting LLC, Seattle, WA 98117, USA. Electronic address: jwalson@walsonconsultingllc.com.

PMID: 39389075
DOI: 10.1016/S1473-3099(24)00615-7

No abstract available

Publication types

Letter